Cargando…

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis

Cardiac hypertrophy initially serves as an adaptive response to physiological and pathological stimuli. Sustained hypertrophy progress to pathological cardiac hypertrophy, cardiac fibrosis and ultimately lead to heart failure, one of the leading medical causes of mortality worldwide. Intervention of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yan, Zhou, Junteng, Wei, Zisong, Cheng, Yue, Tian, Geer, Quan, Yue, Kong, Qihang, Wu, Wenchao, Liu, Xiaojing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393479/ https://www.ncbi.nlm.nih.gov/pubmed/36003513 http://dx.doi.org/10.3389/fphar.2022.940768

Ejemplares similares

P2Y1 Receptor Agonist Attenuates Cardiac Fibroblasts Activation Triggered by TGF-β1
por: Tian, Geer, et al.
Publicado: (2021)

Purinergic P2 Receptors: Novel Mediators of Mechanotransduction
por: Kong, Qihang, et al.
Publicado: (2021)

Voltage-dependent anion channel 1 (VDAC1) overexpression alleviates cardiac fibroblast activation in cardiac fibrosis via regulating fatty acid metabolism
por: Tian, Geer, et al.
Publicado: (2023)

The long noncoding RNA THBS1-AS1 promotes cardiac fibroblast activation in cardiac fibrosis by regulating TGFBR1
por: Zhou, Junteng, et al.
Publicado: (2023)

Inhibition of P2X7 Purinergic Receptor Ameliorates Cardiac Fibrosis by Suppressing NLRP3/IL-1β Pathway
por: Zhou, Junteng, et al.
Publicado: (2020)

Mitochondrial ROS-Modulated mtDNA: A Potential Target for Cardiac Aging
por: Quan, Yue, et al.
Publicado: (2020)

Circular RNAs in the regulation of cardiac hypertrophy
por: Wu, Siyi, et al.
Publicado: (2021)

tRNA-Derived Small RNAs and Their Potential Roles in Cardiac Hypertrophy
por: Cao, Jun, et al.
Publicado: (2020)

Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis
por: Wang, Juan, et al.
Publicado: (2016)

Quercetin Attenuates Cardiac Hypertrophy by Inhibiting Mitochondrial Dysfunction Through SIRT3/PARP-1 Pathway
por: Chen, Wen-Jing, et al.
Publicado: (2021)

Energy Metabolism in Exercise-Induced Physiologic Cardiac Hypertrophy
por: Xiang, Kefa, et al.
Publicado: (2020)

Si-Miao-Yong-An Decoction Protects Against Cardiac Hypertrophy and Dysfunction by Inhibiting Platelet Aggregation and Activation
por: Su, Congping, et al.
Publicado: (2019)

Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway
por: Zhao, Tingwei, et al.
Publicado: (2021)

Scaffold Proteins Regulating Extracellular Regulated Kinase Function in Cardiac Hypertrophy and Disease
por: Liang, Yan, et al.
Publicado: (2016)

MicroRNAs in Cardiac Hypertrophy
por: Wehbe, Nadine, et al.
Publicado: (2019)

MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload
por: Ji, Yue, et al.
Publicado: (2018)

Editorial: Cardiac Hypertrophy: From Compensation to Decompensation and Pharmacological Interventions
por: Liu, Ya, et al.
Publicado: (2021)

Role of PI3-Kinase in Angiotensin II-Induced Cardiac Hypertrophy: Class I Versus Class III
por: Zhong, Tiecheng, et al.
Publicado: (2021)

Circular RNAs in the Regulation of Oxidative Stress
por: Zhang, Yao, et al.
Publicado: (2021)

Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy
por: Zhen, Changlin, et al.
Publicado: (2023)

MicroRNAs Regulating Mitochondrial Function in Cardiac Diseases
por: Zhang, Guang-Qiong, et al.
Publicado: (2021)

QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway
por: Anwaier, Gulinigaer, et al.
Publicado: (2022)

Gastrodin Inhibits Store-Operated Ca(2+) Entry and Alleviates Cardiac Hypertrophy
por: Zheng, Changbo, et al.
Publicado: (2017)

Anthocyanin Protects Cardiac Function and Cardiac Fibroblasts From High-Glucose Induced Inflammation and Myocardial Fibrosis by Inhibiting IL-17
por: Yue, Er, et al.
Publicado: (2021)

Extracellular signal-regulated kinases 1/2 as regulators of cardiac hypertrophy
por: Mutlak, Michael, et al.
Publicado: (2015)

Circular RNA expression in isoproterenol hydrochloride-induced cardiac hypertrophy
por: Yang, Ming-Hui, et al.
Publicado: (2020)

Liquiritin Attenuates Pathological Cardiac Hypertrophy by Activating the PKA/LKB1/AMPK Pathway
por: Aiyasiding, Xiahenazi, et al.
Publicado: (2022)

Commentary: Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy
por: Liu, Zengying, et al.
Publicado: (2022)

Non‐coding RNAs in cardiac hypertrophy
por: Ottaviani, Lara, et al.
Publicado: (2017)

Effect of Triptolide on Temporal Expression of Cell Cycle Regulators During Cardiac Hypertrophy
por: Li, Jing-Mei, et al.
Publicado: (2020)

Therapeutic Potential of Polyphenols in Cardiac Fibrosis
por: Zhang, Ning, et al.
Publicado: (2018)

SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
por: Lin, Hui, et al.
Publicado: (2021)

Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism
por: Zhang, Xiaoying, et al.
Publicado: (2021)

Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
por: Zhang, Yaxing, et al.
Publicado: (2016)

Cardioprotective Effect of Ulmus wallichiana Planchon in β-Adrenergic Agonist Induced Cardiac Hypertrophy
por: Syed, Anees A., et al.
Publicado: (2016)

Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy
por: Yu, Jing, et al.
Publicado: (2021)

Effects of Sodium Ferulate on Cardiac Hypertrophy Are via the CaSR-Mediated Signaling Pathway
por: Chen, Panpan, et al.
Publicado: (2021)

Ang II Promotes Cardiac Autophagy and Hypertrophy via Orai1/STIM1
por: Zheng, Chang-Bo, et al.
Publicado: (2021)

Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy
por: Zhang, Hua, et al.
Publicado: (2022)

CXCR4 Antagonism Reduces Cardiac Fibrosis and Improves Cardiac Performance in Dilated Cardiomyopathy
por: Chu, Po-Yin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ggebjfee9oooc5ue9b8kibeovo